
2025-03-09
Ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza igxile ekuletheni ama-ejenti okwelapha ikakhulukazi amangqamuzana omdlavuza, ukunciphisa ukulimala kwezicubu ezinempilo. Le ndlela isebenzisa amasu ahlukahlukene, okuhlanganisa ama-nanoparticles, amasosha omzimba, nama-peptide angena kumaseli, ukuze kuthuthukiswe ukusebenza kahle kwezidakamizwa nokunciphisa imiphumela engemihle, inikeze ukwelashwa komdlavuza okunembe kakhudlwana futhi komuntu siqu.
Ukwelashwa komdlavuza kuye kwavela kakhulu, nge ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza okuvela njengesu elithembisayo. Le ndlela ihlose ukuletha izidakamizwa ngokukhetha kumaseli omdlavuza, ukwandisa imiphumela yokwelapha ngenkathi kunciphisa ukulimala kwezicubu ezinempilo. Ngokungafani ne-chemotherapy evamile, esabalalisa izidakamizwa emzimbeni wonke, ukulethwa okuhlosiwe kusebenzisa izindlela ezihlukahlukene ukukhomba ngokunembile amangqamuzana omdlavuza.
Ukwelashwa ngamakhemikhali endabuko kuvame ukuholela emiphumeleni engathandeki ephawulekayo ngoba kuthinta kokubili amangqamuzana anomdlavuza nanempilo. Ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza inikeza isixazululo ngokuletha izidakamizwa ngqo endaweni yesimila. Lokhu kunciphisa ubuthi besistimu, kuthuthukisa ukusebenza kwezidakamizwa, futhi kuthuthukisa izinga lempilo yesiguli.
Kusetshenziswa amasu amasha amaningana ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza, ngayinye inezinzuzo zayo nokulinganiselwa kwayo.
Ama-nanoparticles ayizinhlayiya ezincane (1-100 nm) eziklanyelwe ukuhlanganisa nokuletha izidakamizwa kumaseli omdlavuza. Angakhiwa ukuze aqondise ama-receptors athile kumaseli omdlavuza, njenge-EGFR noma i-HER2. Ama-Liposomes, ama-nanoparticles e-polymeric, nama-nanoparticles angaphili avame ukusetshenziswa. Umphumela othuthukisiwe wokufinyeleleka nokugcinwa (EPR) uvumela ama-nanoparticles ukuthi anqwabelene kancane ezicutshini zesimila ngenxa yokuvuza kwe-vasculature.
Isibonelo: I-Doxil, i-liposomal doxorubicin, isidakamizwa esisekelwe ku-nanoparticle esithengiswayo esisetshenziselwa ukwelapha umdlavuza wesibeletho kanye ne-myeloma eminingi.
Ama-ADC aqukethe i-monoclonal antibody exhunywe kumuthi we-cytotoxic. I-antibody ibophezela ngokuqondile ku-antigen eqondiwe kumaseli omdlavuza, okuholela ekufakweni ngaphakathi kwe-ADC kanye nokukhululwa komuthi okulandelayo ngaphakathi kweseli.
Isibonelo: I-Adcetris (i-brentuximab vedotin) ihlose i-CD30, iphrotheni etholakala kumaseli athile e-lymphoma, ihambisa i-microtubule-disrupting agent.
Ama-CPP ama-amino acid amafushane alandelanayo enza kube lula ukungena kwezidakamizwa noma ama-nanoparticles kumaseli. Zingahlanganiswa nama-agent okwelapha noma ama-nanoparticles ukuze kuthuthukiswe ukutholakala kwamaselula.
Leli su libandakanya ukukhomba ama-receptors agcizelelwe ngokweqile kumaseli omdlavuza. Ama-ligand noma amasosha omzimba abopha kulawa ma-receptors asetshenziselwa ukuletha izidakamizwa noma ama-nanoparticles nge-endocytosis.
I-Shandong Baofa Cancer Research Institute ibambe iqhaza elikhulu ekucwaningeni nasekuthuthukiseni inoveli ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza izinhlelo. Ucwaningo lwabo lugxile ezindleleni eziqondene nawe ezicabangela amaphrofayili ofuzo namamolekyuli ahlukile esiguli ngasinye, okuhloswe ngawo ukuthuthukisa imiphumela yokwelashwa kanye nokunciphisa imiphumela engemihle.
I-Shandong Baofa Cancer Research Institute isebenza nezibhedlela ezifana ne-Shandong Baofa Cancer Hospital (https://baofahospital.com) ukwenza izivivinyo zemitholampilo kanye nokuhumusha okutholwe ocwaningweni kube izinhlelo zokusebenza ezingokoqobo.
Ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza inikeza izinzuzo ezimbalwa ezibalulekile ngaphezu kwe-chemotherapy evamile:
Naphezu kwesithembiso sayo, ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza ibhekene nezinselelo ezimbalwa:
Eziningana ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza amasistimu okwamanje avunyelwe ukusetshenziswa emtholampilo:
| Igama lezidakamizwa | Ithagethi | Uhlobo lweCancer | Indlela Yokudiliva |
|---|---|---|---|
| I-Doxil (i-liposomal doxorubicin) | Ukuqondisa okwenziwayo ngomphumela we-EPR | Umdlavuza we-Ovarian, i-Myeloma eminingi | I-Liposomes |
| I-Adcetris (brentuximab vedotin) | CD30 | I-Hodgkin lymphoma, i-Anaplastic cell lymphoma enkulu | I-antibody-drug conjugate (ADC) |
| I-Kadcyla (trastuzumab emtansine) | I-HER2 | HER2-positive umdlavuza webele | I-antibody-drug conjugate (ADC) |
Inkambu ye ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza ikhula ngokushesha. Ucwaningo lwangomuso luzogxila kulokhu:
Ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza unesithembiso esikhulu sokuthuthukisa ukwelashwa komdlavuza kanye nemiphumela yesiguli. Njengoba ucwaningo luqhubeka, singalindela ukubona ngempumelelo kakhudlwana futhi okomuntu siqu ukulethwa kwezidakamizwa ezihlosiwe zomdlavuza amasu ayavela, ekugcineni aholele ekunakekelweni komdlavuza okungcono.